Form 4: Zivo Bioscience Director Mark Strome Acquires Shares and Warrants

Director Mark Strome, through related entities, acquired 75,000 shares and 7,500 warrants of Zivo Bioscience at $20.19 per share.

Summary

• Mark Strome, a director of Zivo Bioscience, acquired 75,000 shares of common stock and 7,500 common stock purchase warrants on December 26, 2024.
• The shares and warrants were acquired at a price of $20.19 per share.
• The transactions were made indirectly through Strome Mezzanine Fund II, LP.
• Strome Investment Management, LP is the general partner of Strome Mezzanine Fund II, LP, and Strome Group, Inc. is the general partner of Strome Investment Management, LP.
• Mark E. Strome is the President and CEO of Strome Group, Inc.
• Following the transaction, the reporting entities beneficially own 398,683 shares and 44,171 warrants.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the director's purchase is a positive sign, the disclaimer of beneficial ownership and the indirect nature of the transaction temper the positive impact.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.
• The purchase of both shares and warrants suggests a long-term commitment.

Risks

• The filing includes a disclaimer of beneficial ownership, except to the extent of pecuniary interest, which could indicate a complex ownership structure.
• The indirect nature of the transaction through multiple entities may obscure the true extent of the director's personal investment.

Management Comments

• The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, except to the extent of their pecuniary interest therein.

Industry Context

Insider trading activity is closely monitored by regulators and investors as it can provide insights into management's view of the company's prospects. This transaction is a routine disclosure of such activity.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders.
• The transaction is similar to other insider purchases, where directors or officers acquire shares or options in their company.

Stakeholder Impact

• The share purchase may be viewed positively by shareholders as it indicates confidence from a company director.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Zivo Bioscience, insider trading, Form 4, Mark Strome, share acquisition, warrant acquisition, beneficial ownership, Strome Mezzanine Fund II, director